Company Overview Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECH TM drug delivery technology.
Phase 1 · ActiveModality: DehydraTECH oral drug delivery formulation
Indications
Hypertension(Phase 1)
Status note IND Study May Proceed letter received Feb 29, 2024 for Phase 1b study HYPER-H23-1; FDA agreed to 505(b)(2) NDA pathway; company maintaining active IND status while seeking funding to commence the study.
DehydraTECH oral GLP-1/GIP/glucagon program
Phase 1 · ActiveModality: DehydraTECH oral drug delivery formulation
Aliases DHT-LIR
Target GLP-1 / GIP / glucagon receptors
Partnerships PharmaCO: material transfer agreement extended through Dec 30, 2026 (unnamed pharmaceutical company)
Indications
Diabetes / weight loss(Phase 1)
Catalysts
— Q4 fiscal 2026
— Q4 fiscal 2026
Status note Phase 1b GLP-1-H24-4 (DehydraTECH CBD + semaglutide, tirzepatide) completed Dec 2025; Human Pilot Study GLP-1-H25-5 (oral DehydraTECH-liraglutide vs Saxenda) positive; Human Pilot Study #7 (GLP-1-H26-7, oral DehydraTECH-semaglutide vs Wegovy) ethics-approved.
Per-asset detail extracted from the 10-Q filed 2026-07-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.